Acadia Revives Nuplazid’s Chances In Schizophrenia With Negative Symptom Data

 
• By Joseph Haas
Schizophrenia
Acadia's data may point to an approval in negative symptoms of schizophrenia

More from Clinical Trials

More from R&D